Bausch Health Companies Inc (VRX) - Medical Equipment - Deals and Alliances Profile

Bausch Health Companies Inc (VRX) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME3707D
  • |
  • Pages: 119
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Bausch Health Companies Inc(Bausch Health) formerly known as Valeant Pharmaceuticals International Inc, develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Bausch Health offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Bausch Health is headquartered in Laval, Quebec, Canada.

Bausch Health Companies Inc (VRX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Bausch Health Companies Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 9

Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Bausch Health Companies Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11

Bausch Health Companies Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12

Bausch Health Companies Inc, Medical Equipment, Deal Details 15

Asset Purchase 15

Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 15

Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 16

Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 17

Private Equity 18

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 18

Partnerships 19

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 19

Namtall Enters into Licensing Agreement with Valeant Pharma 21

Bausch & Lomb Enters Into Licensing Agreement With Cirle 22

Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 23

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 24

Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 25

Valeant Pharmaceuticals International Partners With Living Proof 26

Obagi Medical Products Extends Distribution Agreement With Suneva Medical 27

Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 28

Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 29

Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 30

Solta Medical Expands Co-Marketing Agreement With SkinCeuticals 31

Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 32

Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 33

Solta Medical Enters Into Co-Marketing Agreement With SkinCeuticals 34

OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 35

Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 36

Equity Offering 37

Valeant Pharma Plans to Raise Funds through Public Offering of Securities 37

Bausch & Lomb Withdraws IPO 38

Solta Medical Completes Public Offering Of Common Stock For USD 17 Million 39

Debt Offering 40

Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 40

Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 41

Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 42

Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 43

Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 44

Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 45

Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 46

Solta Medical Completes Private Placement Of Debt Securities For USD 40 Million 47

Valeant Pharma Completes Private Placement Of Notes Due 2020 For USD 1.75 Billion 48

Valeant Pharma Completes Private Placement Of Notes Due 2020 For USD 500 Million 49

Asset Transactions 50

Valeant Pharma International May Sell Eye Surgery Assets to Carl Zeiss Meditec 50

Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 51

Almirall Plans to Acquire Dermatology Assets from Valeant Pharmaceuticals 52

Stryker Acquires Neuro Portfolio Assets of Synergetics 53

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 54

Acquisition 55

Valeant Pharma Sells Sprout Pharma 55

Pershing Square Capital Management Sells its Investment in Valeant Pharma 56

Bausch & Lomb Acquires Doctor's Allergy Formula 57

Valeant Pharma Acquires Synergetics 58

Valeant Pharma to Acquire Unilens Vision 60

Valeant Canada Acquires CROMA Pharma Canada 61

Valeant Pharma Completes Acquisition Of Solta Medical For USD 250 Million 62

Valeant Pharma Completes Acquisition Of Bausch & Lomb For USD 8.7 Billion 64

Synergetics USA Acquires M.I.S.S. Ophthalmics For USD 3 Million 66

OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 67

Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 68

Solta Medical Completes Acquisition Of Sound Surgical For Up To USD 40 Million 69

Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For USD 631 Million 70

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 72

Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For USD 10 Million 74

Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For USD 442 Million 75

Bausch Health Companies Inc-Key Competitors 76

Bausch Health Companies Inc-Key Employees 77

Bausch Health Companies Inc-Locations And Subsidiaries 78

Head Office 78

Other Locations & Subsidiaries 78

Recent Developments 87

Financial Announcements 87

May 08, 2018: Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance 87

Feb 28, 2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results 90

Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results 94

Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 96

May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 99

Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 100

Corporate Communications 104

Sep 15, 2017: Valeant Commits USD 200,000 to Support Hurricane Relief Efforts 104

Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 105

Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 106

Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 107

May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 108

Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 109

Legal and Regulatory 110

Sep 28, 2018: Salix Resolves Legacy SEC Investigation With No Penalty 110

May 15, 2018: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors 111

May 08, 2018: Valeant Will Become Bausch Health Companies 112

Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 113

Product News 114

Apr 27, 2018: Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting 114

May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 116

Other Significant Developments 117

Sep 27, 2018: Bausch Health Releases First Annual Corporate Social Responsibility Report 117

Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program 118

Appendix 119

Methodology 119

About GlobalData 119

Contact Us 119

Disclaimer 119

List of Figures

Bausch Health Companies Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Bausch Health Companies Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Bausch Health Companies Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9

Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Bausch Health Companies Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

List of Tables

Bausch Health Companies Inc, Medical Equipment, Key Facts, 2017 2

Bausch Health Companies Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Bausch Health Companies Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 9

Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Bausch Health Companies Inc, Deals By Market, 2012 to YTD 2018 11

Bausch Health Companies Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12

Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 15

Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 16

Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 17

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 18

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 19

Namtall Enters into Licensing Agreement with Valeant Pharma 21

Bausch & Lomb Enters Into Licensing Agreement With Cirle 22

Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 23

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 24

Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 25

Valeant Pharmaceuticals International Partners With Living Proof 26

Obagi Medical Products Extends Distribution Agreement With Suneva Medical 27

Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 28

Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 29

Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 30

Solta Medical Expands Co-Marketing Agreement With SkinCeuticals 31

Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 32

Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 33

Solta Medical Enters Into Co-Marketing Agreement With SkinCeuticals 34

OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 35

Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 36

Valeant Pharma Plans to Raise Funds through Public Offering of Securities 37

Bausch & Lomb Withdraws IPO 38

Solta Medical Completes Public Offering Of Common Stock For USD 17 Million 39

Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 40

Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 41

Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 42

Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 43

Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 44

Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 45

Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 46

Solta Medical Completes Private Placement Of Debt Securities For USD 40 Million 47

Valeant Pharma Completes Private Placement Of Notes Due 2020 For USD 1.75 Billion 48

Valeant Pharma Completes Private Placement Of Notes Due 2020 For USD 500 Million 49

Valeant Pharma International May Sell Eye Surgery Assets to Carl Zeiss Meditec 50

Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 51

Almirall Plans to Acquire Dermatology Assets from Valeant Pharmaceuticals 52

Stryker Acquires Neuro Portfolio Assets of Synergetics 53

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 54

Valeant Pharma Sells Sprout Pharma 55

Pershing Square Capital Management Sells its Investment in Valeant Pharma 56

Bausch & Lomb Acquires Doctor's Allergy Formula 57

Valeant Pharma Acquires Synergetics 58

Valeant Pharma to Acquire Unilens Vision 60

Valeant Canada Acquires CROMA Pharma Canada 61

Valeant Pharma Completes Acquisition Of Solta Medical For USD 250 Million 62

Valeant Pharma Completes Acquisition Of Bausch & Lomb For USD 8.7 Billion 64

Synergetics USA Acquires M.I.S.S. Ophthalmics For USD 3 Million 66

OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 67

Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 68

Solta Medical Completes Acquisition Of Sound Surgical For Up To USD 40 Million 69

Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For USD 631 Million 70

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 72

Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For USD 10 Million 74

Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For USD 442 Million 75

Bausch Health Companies Inc, Key Competitors 76

Bausch Health Companies Inc, Key Employees 77

Bausch Health Companies Inc, Other Locations 78

Bausch Health Companies Inc, Subsidiaries 78

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bausch Health Companies Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18225
Site License
USD 500 INR 36450
Corporate User License
USD 750 INR 54675

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com